Summary of GWAS and replication analyses.

5,796 (904 in GWAS, 2,783 in stage2 and 2,109 in stage 3/replication) Nephrolithiasis cases and 17,344 (7,471 in GWAS and 5,251 in stage2 and 4,622 in stage3/replication) controls were analyzed. aMAF: minor allele frequency. bP value obtained from Cochrane-Armitage trend test. cOdds ratios (OR) and confidence interval (CI) are calculated using the non-susceptible allele as reference. dCombined: Odds ratio and P value for independence test were calculated by Mendel-hauzen and Laird method in the Meta-analysis. eThe P values of heterogeneities (Phet) across three stages examined by using the Breslow-Day test.